Reporting suspected adverse reactions to new commercialized medicines in real world.

^*Autor corresponent d’aquest treball

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

1 Citació (Scopus)

Keywords

@article{b622311ad4ef4888b2007698a0775d55,

title = "Reporting suspected adverse reactions to new commercialized medicines in real world.",

keywords = "Alemtuzumab, Autoimmune haemolytic anaemia, Alemtuzumab, Autoimmune haemolytic anaemia, Alemtuzumab, Autoimmune haemolytic anaemia",

author = "{Agusti Escasany}, {M. Antonieta}",

year = "2018",

month = may,

language = "English",

volume = "24",

pages = "816--817",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "6",

}

TY - JOUR

T1 - Reporting suspected adverse reactions to new commercialized medicines in real world.

AU - Agusti Escasany, M. Antonieta

PY - 2018/5

Y1 - 2018/5

KW - Alemtuzumab

KW - Autoimmune haemolytic anaemia

KW - Alemtuzumab

KW - Autoimmune haemolytic anaemia

KW - Alemtuzumab

KW - Autoimmune haemolytic anaemia

M3 - Article

SN - 1352-4585

VL - 24

SP - 816

EP - 817

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 6

ER -